openPR Logo
Press release

Pradaxa Side Effects Lawsuits Filed in Federal Court

03-08-2012 03:03 AM CET | Politics, Law & Society

Press release from: Nadrich & Cohen LLP

Nadrich & Cohen, LLP reports that three Pradaxa side effects lawsuits have been filed in federal courts across the country.

Los Angeles, CA, March 7, 2012 – National law firm Nadrich & Cohen, LLP has learned that three Pradaxa side effects lawsuits have been filed against Boehringer Ingelheim, the drug’s manufacturer. The cases were filed in federal district courts located in Tennessee, Kentucky and Louisiana and it’s believed they are the first federal lawsuits to be filed in connection with the drug.

Pradaxa (dabigatran) was first approved by the U.S. Food and Drug Administration in 2010 to prevent blood clots and strokes in patients who suffer from a heart rhythm defect known as atrial fibrillation (AF). The drug was designed to be a safer alternative to other blood-thinning medications on the market but has become the subject of scrutiny after research studies have linked Pradaxa to an increased risk of serious bleeding events.

One of the lawsuits filed against Boehringer blames Pradaxa for the wrongful death of a Tennessee woman who began using the drug in January 2011 to treat her atrial fibrillation. According to the woman’s daughter, who filed the suit, Pradaxa caused her to suffer a massive gastrointestinal bleed, which resulted in her death less than three months after she began taking the drug.

In November 2011, Boehringer acknowledged that as many as 260 deaths worldwide had been linked to Pradaxa. The FDA issued an updated safety communication in December 2011, warning patients and health care providers about the potential link between the drug and bleeding risk. The FDA did, however, state that Pradaxa’s benefits outweighed the risk and advised patients to seek medical advice before discontinuing its use.

Just last week, a group of hematologist from New Zealand and Australia announced that a two-month investigative review uncovered 78 cases of bleeding related to Pradaxa, with 44 of these patients experiencing major bleeding events. The researchers, who discussed their findings in a letter to the editor published in the March 1 issue of the New England Journal of Medicine, suggested that at least one patient may have died in connection with prolonged internal bleeding caused by Pradaxa.

Patients who suffered a serious bleeding event or other complications after using Pradaxa are urged to complete a MedWatch form by visiting the Food and Drug Administration’s website. It is also recommended that you contact an experienced Pradaxa injury attorney to discuss your legal rights.

Attorney Jeffrey Nadrich believes that these lawsuits are just the first of many that will likely be filed in connection with injuries or deaths caused by Pradaxa. Nadrich & Cohen LLP offers confidential, no-cost consultations to Pradaxa users who believe they were harmed by the drug. Help is available by calling 1-800-722-0765 or by completing an online case evaluation form at www.personalinjurylawcal.com.

Nadrich & Cohen LLP is a national law firm with offices in Los Angeles, Sacramento, San Diego and other cities throughout California. The firm specializes in handling mass tort actions and representing individuals in cases involving pharmaceutical companies, medical device makers and other product manufacturers. The firm is committed to achieving the best outcome possible in every case and has recovered over $200 million in settlements on behalf of its clients.

In addition to handling Pradaxa side effects claims, Nadrich & Cohen, LLP investigates cases involving Actos, Yaz, Vaginal Mesh, DePuy ASR Hips, Zimmer Hips, Wright Conserve Hips, Stevens-Johnson Syndrome, Reflex Sympathy Dystrophy, Fen Phen and PPH, Depakote and Reglan.

Jennifer Poole
National Client Intake Coordinator
Nadrich & Cohen LLP
12100 Wilshire Blvd.
Suite 1250
Los Angeles, CA 90025
800-718-4658
info@personalinjurylawcal.com
www.personalinjurylawcal.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Pradaxa Side Effects Lawsuits Filed in Federal Court here

News-ID: 213540 • Views:

More Releases from Nadrich & Cohen LLP

Yaz Lawsuit Settlements Reach $142 Million
Nadrich & Cohen, LLP reports that Bayer is continuing to offer settlements to plaintiffs involved in federal Yaz side effects litigation. Los Angeles, CA, April 27, 2012 – Nadrich & Cohen, LLP reports that German drug-maker Bayer AG has settled approximately 651 Yaz side effects lawsuits totaling $142 million. Earlier this month, it was reported that the drug-maker had reached settlements in approximately 500 cases filed by women who claimed
Yaz, Yasmin to Get New Labels as FDA Warns of Blood Clot Risk
Nadrich & Cohen, LLP reports that Yaz and similar birth control pills are to receive updated warning labels advising patients of the risk for developing serious blood clots. Los Angeles, CA, April 10, 2012 – National law firm Nadrich & Cohen, LLP has learned that the U.S. Food and Drug Administration has ordered Bayer to produce new warning labels for several of its oral contraceptives, including Yaz, Yasmin and Beyaz.
FDA Schedules Advisory Panel Meeting to Discuss Metal Hip Safety
Nadrich & Cohen, LLP reports that the FDA has scheduled an advisory panel to discuss the safety of metal hip implants. Los Angeles, CA, March 29, 2012 – National law firm Nadrich & Cohen, LLP has learned that the U.S. Food and Drug Administration has a scheduled an advisory panel meeting to discuss the safety of metal hip implants and all-metal hip resurfacing systems. The two-day panel, which is expected
Bayer Agrees to Settlement in 70 Yaz Side Effects Lawsuits
Nadrich & Cohen, LLP reports that Bayer has agreed to settlements with a number of plaintiffs who sued the company over Yaz side effects. Los Angeles, CA, March 5, 2012 – National law firm Nadrich & Cohen, LLP reports that Bayer Healthcare has agreed to settle approximately 70 lawsuits filed on behalf of women who claim they were seriously injured by Yaz birth control pills. The amount of the settlements has

All 5 Releases


More Releases for Pradaxa

Pradaxa Market
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- The global Pradaxa Market is expected to record a CAGR of XX.X% from 2024 to 2031 In 2024, the market size is projected to reach a valuation of USD XX.X Billion. By 2031 the valuation is anticipated to reach USD XX.X Billion. Pradaxa Market Size And Scope The Pradaxa market has shown steady growth, primarily driven by the increasing prevalence of thromboembolic disorders such as atrial fibrillation and deep
Pradaxa Market is Rising in Upcoming Years | 2024-2031
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- The global Pradaxa Market is expected to record a CAGR of XX.X% from 2024 to 2031 In 2024, the market size is projected to reach a valuation of USD XX.X Billion. By 2031 the valuation is anticipated to reach USD XX.X Billion. The impact of manufacturers on the market is significant across various industries, influencing supply chains, consumer choices, and economic growth. Manufacturers are key players in the
Global Anticoagulants Market 2019 Edition Report: Key Major Players are Bayer, B …
The report entitled “Global Anticoagulants Market (2019-2023 Edition)” provides an in-depth analysis of the global anticoagulants market with description of market size and growth. The analysis include market share by segment, and by products. Download Sample Brochure @ http://www.marketreportsonline.com/contacts/requestsample.php?name=784670 The report also provides an analysis of injectable and oral anticoagulants available in the market. Details of Lovenox, Arixtra, Xarelto, Eliquis, Pradaxa and Savaysa has been provided in the report in terms
Pradaxa Global Industry Report - History, Present and Future 2018
GET SAMPLE REPORT @ https://www.research2reports.com/sample-report-other-reports/pradaxa-market/71821 The global market size of Pradaxa is $XX million in 2017 with XX CAGR from 2013 to 2017, and it is expected to reach $XX million by the end of 2023 with a CAGR of XX% from 2018 to 2023. There are 3 key segments covered in this report: geography segment, end use/application segment and competitor segment. For geography segment, regional supply, application-wise and type-wise demand, major
Global Anticoagulants Market: Size, Trends & Forecasts 2017-2021: Key Players ar …
Researchmoz added Most up-to-date research on "Global Anticoagulants Market: Size, Trends & Forecasts (2017-2021)" to its huge collection of research reports. The report entitled Global Anticoagulants Market: Size, Trends & Forecasts (2017-2021) provides an in-depth analysis of the global anticoagulants market with description of market size and growth. The analysis include market share by treatment, by segment, and by products. The report also provides analysis of injectable and oral anticoagulants available in
Atrial Fibrillation-Market Insights & Drugs Sales Forecast (AF) -2020 Regions,Ap …
Atrial Fibrillation-Market Insights & Drugs Wiseguyreports.Com Adds “Atrial Fibrillation-Market Insights & Drugs Market -Market Demand, Growth, Opportunities, Manufacturers, Analysis of Top Key Players and Forecast to 2022” To Its Research Database. Get Sample Report @ https://www.wiseguyreports.com/sample-request/476536-atrial-fibrillation-market-insights-drugs-sales-forecast-af-2020 Covered In This Report: Summary The Atrial Fibrillation-Market Insights & Drugs Sales Forecast (AF) -2020 report provides an overview of the disease, epidemiology and global market trends for the seven major markets ie: United States,